The Zhitong Finance App learned that True Healthcare-B (02697) reversed the market and rose more than 5%. As of press release, it rose 4.30% to HK$276.4, with a turnover of HK$18.138,700.
According to the news, on September 2, the National Health Insurance Administration announced the 3.0 sub-plan for payment by patient group and disease type (DRG/DIP). For the first time, robot-assisted surgery was set up as a separate group; in addition to open, laparoscopy, endoscopy, and thoracoscopy, percutaneous was also listed as an independent category. According to public information, True Health Medical's surgical robot product line covers both puncture and ablation, which fall under this technical path; in addition, the company has also extended its products to external organ preservation and evaluation.
It is worth noting that recently, True Healthcare signed a sales contract with an independent third party to sell puncture navigation and positioning systems to the buyer. The total contract amount is close to RMB 100 million, and related products will be delivered one after another in the near future. The board of directors believes that the conclusion and subsequent delivery of this contract is expected to further expand the company's installed base, drive the growth of equipment revenue, create conditions for the continuous increase in consumables and service revenue, drive the accelerated operation of the “equipment - consumables - service” continuous business model, and benefit more patients with accurate and minimally invasive diagnosis and treatment.